Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
Lead test on track for 200 million covered lives and beneficiaries by early 2027 after CMS meetingOn track to launch expanded CNSide testing menu with multiple tests in Q4 2026HOUSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. NASDAQ:CNSY ("Cerenome" or the "Company") today provided a third…